ABSTRACT
Background Gangliosides - glycosphingolipids that modulate cell signaling and neuronal functions - are decreased in Huntington’s disease (HD) models and patients’ brains. Restoring ganglioside GM1 has therapeutic benefits in HD mice, slowing neurodegeneration and improving symptoms. This suggests gangliosides might contribute to HD pathogenesis. However, their link to disease severity and progression in patients remains unclear.
Objectives This study examined plasma ganglioside differences between HD gene carriers and controls, and their prognostic potential.
Methods Plasma gangliosides were quantified in 67 HD carriers and 46 healthy participants, using liquid chromatography-tandem mass spectrometry. Statistical modelling assessed associations with clinical measures and prognostic potential.
Results Levels of most gangliosides were similar between groups, but GM3 was higher and GT1b lower in HD carriers. Within the HD group, higher GM2 levels correlated with better cognition, and higher GM1 and GD1a with greater functional capacity and independence. Higher GM1 predicted HD status, but its decline and an increase in GD3 were strongly associated with disease progression. Individual gangliosides had limited disease classification ability.
Conclusions The correlation between higher GM2, GD1a and GM1 and milder symptoms suggests a protective role of these gangliosides in HD. The association between higher GM1 levels and HD status, along with its decline predicting disease progression, suggests GM1 increase may be a compensatory neuroprotective mechanism that deteriorates over time. While plasma gangliosides are not strong disease classifiers, our findings provide novel insights into their role in HD progression and prognostic potential.
Competing Interest Statement
Simonetta Sipione holds a patent for the use of GM1 in Huntington disease (Patent Number US 09023812) and is an Advisory Board Member and consultant for Zulia Inc., USA. There are no other financial disclosure/conflicts to report.
Funding Statement
This work was supported by a Brain Canada Multi-Investigator Research Initiative grant to SS, OS, SC, JC and JS, and by Canadian Institutes of Health Research (CIHR) and GlycoNET grants to SS. We thank the Alberta SPOR SUPPORT Unit and EPICORE at the University of Alberta for statistical support services.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The University of Alberta Health Research Ethics Board gave ethical approval for this work (Pro00067917).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Financial Disclosure/Conflict of interest: SS holds a patent for the use of GM1 in Huntington’s disease (Patent Number US 09023812). There are no other financial disclosure/conflicts to report.
Founding sources: Brain Canada/Huntington Society of Canada, GlycoNET, CIHR
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos